| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6462 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 |
| filingDate |
1992-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a9c744fc3210c4e53fa90a04bad3011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f48e44d8eac17c40d477fd0fdcbe8b1 |
| publicationDate |
1992-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9218139-A1 |
| titleOfInvention |
Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques |
| abstract |
The present invention is directed to compositions and methods of treatment that are useful in thrombolytic therapy. The compositions of the present invention are designed to minimize the bleeding complications that are associated with presently available thrombolytic therapy. Accordingly, the compositions comprise a chimeric molecule constructed with a plasminogen activator moiety that cannot bind to fibrin and a moiety that targets pathologic thrombi. This construction results in a molecule that has affinity only for pathologic thrombi, thus avoiding normal thrombi and circulating components of the fibrinolytic system. The plasminogen activator may be coupled to a specific thrombin inhibitor of the serpin class that will counteract thrombin generation during thrombolysis. The present invention is also directed to compositions and methods of treatment wherein the plasminogen activator is not coupled with the moiety that targets pathologic thrombi, but wherein this moiety is used as a separate adjunct for plasminogen activator therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-1057124-C
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011036444-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9169315-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0714982-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5681721-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6133011-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0714982-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0669394-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5747291-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013505030-A |
| priorityDate |
1991-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |